Left Atrial Appendage Closure | On Demand

Presented at the 29th Annual International
AF Symposium February 2024.

Stroke Risk Management in Atrial Fibrillation Session I


Moderators: Rod Passman, MD and Jonathan Piccini, MD
All lectures 7 minutes. Panel and Audience Discussion 25 minutes.

Anticoagulation in Patients with Implantable Device Detected Atrial High Rate Episodes NOAH-AFNET6 Trial/ARTESIA/other 
Daniel Singer, MD

Factor XI/XIa Inhibitors – Mechanisms, Clinical Outcomes, and Future Directions 
Elaine Hylek, MD

Outcome Severity with Falls on Anticoagulant Drugs vs LAA Closure Devices 
Mingming Ning, MD, MSc

Stroke Severity with Different Stroke Prophylaxis Therapies: DOACs vs LAA Closure Devices
Mohit Turagam, MD

Single Antiplatelet Therapy with New Generation LAA Closure Devices
Walid Saliba, MD
Panel and Audience Discussion (25 minutes) – All Faculty

Stroke Risk Management in Atrial Fibrillation Session II 
Supported by an Educational Grant from Boston Scientific


Moderators: Walid Saliba, MD and Devi Nair, MD
All lectures 7 minutes. Panel and Audience Discussion 25 minutes.

Safety and Efficacy of Watchman FLX: Real World Experience (SURPASS Registry)
James Freeman, MD

ICE Guided Left Atrial Appendage Closure 
Shephal Doshi, MD

Peri-Device Leaks with LAA Closure Devices: What Does the Evidence Show?
Rodney Horton, MD

Concomitant Left Atrial Appendage Closure with Other Cardiac Procedures
Oussama Wazni, MD

New Devices for LAA Closure – Future Directions in Technology
Vivek Reddy, MD

Panel and Audience Discussion – All Faculty & Andrew Farb, MD, Chief Medical Officer, Office of Cardiovascular Devices, CDRH, US FDA